sec annual report filed

We have begun to enter into commercial supply contracts with pharmaceutical customers for the Unifill syringe. The first supply contract is related to the planned launch of a generic equivalent of an approved auto-immune therapy that is currently available in a standard prefilled syringe format for use across several indications. Under the terms of this contract, Unilife has agreed to grant to the pharmaceutical customer an exclusive supply right for the Unifill syringe for a specific indication and Western European territory. The contract further provides that an exclusivity fee will be added onto the negotiated unit price of the Unifill syringe when agreed exclusivity conditions are met.


http://ir.unilife.com/secfiling.cfm?filingid=1193125-12-391039